Curiosis Inc

Curiosis Inc exhibits a strong liquidity position, with a current ratio of 8.8 and cash and equivalents amounting to 23,670,706,920 KRW, indicating a robust ability to meet short-term obligations. The company's price-to-book ratio of 13.53 and price-to-tangible-book ratio of 13.53 suggest that the market is valuing the company significantly above its book value, potentially reflecting expectations of future growth or intangible assets. However, the company's return on equity of -0.2789 and return on assets of -0.2298 indicate that it is currently generating negative returns for shareholders and asset holders. The company's profitability is a concern, as evidenced by its operating income of -7,525,764,110 KRW and net income of -7,864,272,240 KRW. These figures suggest that the company is not currently profitable and is experiencing significant losses. The debt-to-equity ratio of 0.11 indicates a relatively low level of leverage, which may be a positive factor in terms of financial stability. However, the company's operating cash flow of -7,348,638,190 KRW and free cash flow of -9,206,868,440 KRW highlight the challenges it faces in generating positive cash flow from operations. Curiosis Inc's revenue is primarily derived from the development and manufacture of bioresearch equipment, lab automation products, and medical devices. The company's revenue concentration is not explicitly detailed, but its operations are focused on the healthcare sector, which may expose it to specific industry risks. The company's capital expenditure of -2,307,166,300 KRW indicates that it is investing in its operations, which could be a sign of growth initiatives. The company's growth trajectory is uncertain, as reflected in the negative operating and net income figures. Analyst estimates suggest that the company's revenue and earnings are expected to remain negative, with a mean EPS estimate of -92.10 KRW and a mean revenue estimate of 163,000,000 KRW. The company's recent financial performance, including a last actual EPS of -1,203.00 KRW and a last actual revenue of 7,303,000,000 KRW, further underscores the challenges it faces in achieving profitability. The risk assessment for Curiosis Inc indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative operating and net income figures, along with its negative cash flows, suggest that it may face financial challenges in the near term. The company's capital structure, with a low debt-to-equity ratio, may provide some buffer against financial distress, but the negative returns on equity and assets indicate that it is not currently generating value for shareholders. Recent events, including the company's financial performance and analyst estimates, highlight the need for the company to address its profitability and cash flow issues. The company's focus on bioresearch equipment and lab automation products may offer long-term growth opportunities, but the current financial challenges suggest that it will need to implement effective strategies to improve its financial performance.